Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350070 | 0.85 | NAAA (0.40) | HPGDEPHX1EPHX2NAAASMN1; SMN2 | |
| SCHEMBL4350873 | 0.82 | EPHX1 (0.40) | EPHX1EPHX2NAAAALDH1A1TRPV1 | |
| SCHEMBL4356059 | 0.80 | NPC1 (0.50) | HPGDEPHX1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL4358550 | 0.78 | EPHX2 (0.39) | HPGDEPHX1EPHX2NAAATRPV1 | |
| SCHEMBL4348484 | 0.77 | EPHX2 (0.43) | EPHX1EPHX2NAAATRPV1 | |
| SCHEMBL4355852 | 0.77 | EPHX2 (0.48) | EPHX1EPHX2NAAASMN1; SMN2LMNA | |
| SCHEMBL4346809 | 0.77 | TRPV1 (0.46) | EPHX1EPHX2NAAAALDH1A1TRPV1 | |
| SCHEMBL4346130 | 0.74 | CA1 (0.51) | EPHX1EPHX2NAAATRPV1 | |
| SCHEMBL4341634 | 0.74 | ALDH1A1 (0.40) | HPGDEGFRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL4348991 | 0.74 | NAAA (0.52) | EGFRNAAAHTTTRPV1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | HPGD 3561/4885EPHX1 1676/4885EGFR 1661/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | HPGD 3127/4885EPHX1 1334/4885EGFR 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.